

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
28 April 2011 (28.04.2011)

PCT

(10) International Publication Number
WO 2011/050215 A1

(51) International Patent Classification:
C07D 215/56 (2006.01) **C07D 487/08** (2006.01)

(21) International Application Number:
PCT/US2010/053628

(22) International Filing Date:
21 October 2010 (21.10.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/254,634 23 October 2009 (23.10.2009) US

(71) Applicant (for all designated States except US): **VERT-
TEX PHARMACEUTICALS INCORPORATED** [US/
US]; 130 Waverly Street, Cambridge, MA 02139 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **AMBHAIKAR,
Narendra, Bhalchandra** [IN/IN]; 404 Sri Sai Rithvik
Enclave, Kondapur White Fields, Hyderabad 500 084
(IN). **HUGHES, Robert** [GB/US]; 10235 Arrow Rock
Avenue, San Diego, CA 92126 (US). **HURLEY, Dennis,
James** [US/US]; 1513 Black Walnut Drive, San Marcos,
CA 92078 (US). **LEE, Elaine, Chungmin** [US/US]; 303
Third Street, Apt. 316, Cambridge, MA 02142 (US). **LIT-
TLER, Benjamin** [GB/US]; 7016 Ivy Street, Carlsbad,
CA 92011 (US). **NUMA, Mehdi** [FR/US]; 3106 Jemez
Drive, San Diego, CA 92117 (US). **ROEPER, Stefanie**
[DE/US]; 144 Spring Street, Unit #2, Cambridge, MA
02141 (US). **SHETH, Urvi** [IN/US]; 9316 Babauta Road,
Unit #71, San Diego, CA 92129 (US).

(74) Agents: **O'BRIEN, Jonathan, P.** et al.; Honigman Miller
Schwartz and Cohn LLP, 350 East Michigan Avenue,
Suite 300, Kalamazoo, MI 49007-3800 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD,
SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG,
ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: PROCESS FOR PREPARING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE
REGULATOR

(57) Abstract: The present invention relates to processes for preparing solid state forms of N-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide, including Compound 1 Form A, Compound 1 Form A-HCl, Compound 1 Form B, and Compound 1 Form B-HCl, any combination of these forms, pharmaceutical compositions thereof, and methods of treatment therewith.



WO 2011/050215 A1